Occurrence of multidrug resistance to oral antibiotics among Escherichia coli urine isolates from outpatient departments in Germany: Extended-spectrum β-lactamases and the role of fosfomycin

International Journal of Antimicrobial Agents

Volumn 44, Issue 4, 2014, Pages 295-300

  Kresken, Michael ^a,b   Pfeifer, Yvonne ^c   Hafner, Dieter ^d   Wresch, Rebecca ^a   Körber Irrgang, Barbara ^a  

^a Antiinfectives Intelligence GmbH   (Germany)

^b Rhine University of Applied Sciences   (Germany)

^c ROBERT KOCH INSTITUTE   (Germany)

^d HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Community acquired; CTX M 15; Outpatients; ST131; Uropathogen

Indexed keywords

ANTIINFECTIVE AGENT; BETA LACTAMASE;

ADOLESCENT; ADULT; AGED; AMBULATORY CARE; CHILD; CLASSIFICATION; COMMUNITY ACQUIRED INFECTION; DRUG EFFECTS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; FEMALE; GENETICS; GENOTYPE; GERMANY; HUMAN; INFANT; ISOLATION AND PURIFICATION; MALE; MICROBIOLOGY; MIDDLE AGED; MOLECULAR TYPING; MULTIDRUG RESISTANCE; NEWBORN; ORAL DRUG ADMINISTRATION; PRESCHOOL CHILD; URINARY TRACT INFECTION; VERY ELDERLY; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMBULATORY CARE; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; CHILD; CHILD, PRESCHOOL; COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; GENOTYPE; GERMANY; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; MOLECULAR TYPING; URINARY TRACT INFECTIONS; YOUNG ADULT;

EID: 84929574307     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2014.05.020     Document Type: Article

References (30)

1. W.E. Stamm, and S.R. Norrby Urinary tract infections: disease panorama and challenges J Infect Dis 183 Suppl. 1 2001 S1 S4
2. K.G. Naber, G. Schito, H. Botto, J. Palou, and T. Mazzei Surveillance study in Europe and Brazil on clinical aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): implications for empiric therapy Eur Urol 54 2008 1164 1175
3. G. Kahlmeter, and H.O. Poulsen Antimicrobial susceptibility of Escherichia coli from community-acquired urinary tract infections in Europe: the ECO·SENS study revisited Int J Antimicrob Agents 39 2012 45 51
4. J. Rodríguez-Baño, J.C. Alcalá, J.M. Cisneros, F. Grill, A. Oliver, and J.P. Horcajada Community infections caused by extended-spectrum β-lactamase-producing Escherichia coli Arch Intern Med 168 2008 1897 1902
5. M.H. Nicolas-Chanoine, J. Blanco, V. Leflon-Guibout, R. Demarty, M.P. Alonso, and M.M. Caniça Intercontinental emergence of Escherichia coli clone O25:H4-ST131 producing CTX-M-15 J Antimicrob Chemother 61 2008 273 281
6. D. Greenwood Fosfomycin trometamol: activity in vitro against urinary tract pathogens Infection 18 Suppl. 2 1990 S60 S64
7. M. de Cueto, J.R. Hernández, L. López-Cerero, C. Morillo, and A. Pascual Activity of fosfomycin against extended-spectrum β-lactamase producing Escherichia coli and Klebsiella pneumoniae Enferm Infecc Microbiol Clin 24 2006 613 616 [in Spanish]
8. M. Gobernado, L. Valdés, J.I. Alós, C. García-Rey, R. Dal-Ré, and J. García-de-Lomas Antimicrobial susceptibility of clinical Escherichia coli isolates from uncomplicated cystitis in women over a 1-year period in Spain Rev Esp Quimioter 20 2007 68 76
9. C. Rodríguez-Avial, I. Rodríguez-Avial, E. Hernández, and J.J. Picazo Increasing prevalence of fosfomycin resistance in extended-spectrum-β-lactamase-producing Escherichia coli urinary isolates (2005-2009-2011) Rev Esp Quimioter 26 2013 43 46
10. J. Oteo, V. Bautista, N. Lara, O. Cuevas, M. Arroyo, and S. Fernández Parallel increase in community use of fosfomycin and resistance to fosfomycin in extended-spectrum β-lactamase (ESBL)-producing Escherichia coli J Antimicrob Chemother 65 2010 2459 2463
11. S.Y. Lee, Y.J. Park, J.K. Yu, S. Jung, Y. Kim, and S.H. Jeong Prevalence of acquired fosfomycin resistance among extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae clinical isolates in Korea and IS26-composite transposon surrounding fosA3 J Antimicrob Chemother 67 2012 2843 2847
12. International Organization for Standardization ISO 20776-1:2006. Clinical laboratory testing and in vitro diagnostic test systems - susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility test devices - part 1. Reference method for testing the in vitro activity of antimicrobial agents against rapidly growing aerobic bacteria involved in infectious diseases 2006 International Organization for Standardization Geneva, Switzerland
13. European Committee on Antimicrobial Susceptibility Testing (EUCAST) Breakpoint tables for interpretation of MICs and zone diameters. Version 4.0 2014, January 1 http://www.eucast.org/clinical-breakpoints/ [accessed 28.01.14]
14. Clinical and Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing: twenty-first informational supplement. Document M100-S21 2011 CLSI Wayne, PA
15. C. Eller, S. Simon, T. Miller, J.S. Frick, R. Prager, and W. Rabsch Presence of β-lactamases in extended-spectrum-cephalosporin-resistant Salmonella enterica of 30 different serovars in Germany 2005-11 J Antimicrob Chemother 68 2013 1978 1981
16. M. Blanco, M.P. Alonso, M.H. Nicolas-Chanoine, G. Dahbi, A. Mora, and J.E. Blanco Molecular epidemiology of Escherichia coli producing extended-spectrum β-lactamases in Lugo (Spain): dissemination of clone O25b:H4-ST131 producing CTX-M-15 J Antimicrob Chemother 63 2009 1135 1141
17. European Centre for Disease Prevention and Control Antimicrobial resistance surveillance in Europe 2012. Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net) 2013 ECDC Stockholm, Sweden http://www.ecdc.europa.eu/en/publications/Publications/antimicrobial-resistance-surveillance-europe-2012.pdf [accessed 28.01.14]
18. C.D. den Heijer, J. Penders, G.A. Donker, C.A. Bruggeman, and E.E. Stobberingh The importance of gender-stratified antibiotic resistance surveillance of unselected uropathogens: a Dutch Nationwide Extramural Surveillance study PLOS ONE 8 2013 e60497
19. R. Colodner, I. Kometiani, B. Chazan, and R. Raz Risk factor for community-acquired urinary tract infection due to quinolone-resistant E. coli Infection 36 2008 41 45
20. GERMAP 2012 Bericht über den Antibiotikaverbrauch und die Verbreitung von Antibiotikaresistenzen in der Human- und Veterinärmedizin in Deutschland 2014 Antiinfectives Intelligence Rheinbach http://www.p-e-g.org/econtext/germap [accessed 05.05.14]
21. F.M. Wagenlehner, G. Schmiemann, U. Hoyme, R. Fünfstück, E. Hummers-Pradier, and M. Kaase National S3 guideline on uncomplicated urinary tract infection: recommendations for treatment and management of uncomplicated community-acquired bacterial urinary tract infections in adult patients Urologe A 50 2011 153 169 [in German]
22. J.H. Jeon, K. Kim, W.D. Han, S.H. Song, K.U. Park, and J.E. Rhee Empirical use of ciprofloxacin for acute uncomplicated pyelonephritis caused by Escherichia coli in communities where the prevalence of fluoroquinolone resistance is high Antimicrob Agents Chemother 56 2012 3043 3046
23. J. Shin, J. Kim, S.H. Wie, Y.K. Cho, S.K. Lim, and S.Y. Shin Fluoroquinolone resistance in uncomplicated acute pyelonephritis: epidemiology and clinical impact Microb Drug Resist 18 2012 169 175
24. G. Valenza, S. Nickel, Y. Pfeifer, C. Eller, E. Krupa, and V. Lehner-Reindl Extended-spectrum β-lactamase (ESBL)-producing Escherichia coli as intestinal colonizers in the German community Antimicrob Agents Chemother 58 2014 1228 1230
25. M. Arvand, V. Moser, and Y. Pfeifer Prevalence of extended-spectrum-β-lactamase-producing Escherichia coli and spread of the epidemic clonal lineage ST131 in nursing homes in Hesse, Germany J Antimicrob Chemother 68 2013 2686 2688
26. M. Kresken, D. Hafner, B. Körber-Irrgang, and die Studiengruppe Epidemiologie und Resistenzsituation bei klinisch wichtigen Infektionserregern aus dem Hospitalbereich gegenüber Antibiotika. Bericht über die Ergebnisse einer multizentrischen Studie der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V. aus dem Jahre 2010 2013 Antiinfectives Intelligence Rheinbach, Germany http://www.p-e-g.org/econtext/Berichte%20der%20Studien [accessed 28.01.14]
27. L.B. Price, J.R. Johnson, M. Aziz, C. Clabots, B. Johnston, and V. Tchesnokova The epidemic of extended-spectrum-β-lactamase-producing Escherichia coli ST131 is driven by a single highly pathogenic subclone, H30-Rx MBio 4 2013 e00377 e00413
28. W.V. Kern Antibiotika und chemotherapeutika U. Schwabe, D. Paffrath, Arzneiverordnungs - report 2012 2012 Berlin, Heidelberg, Germany Springer Medizinverlag 311 338
29. A.I. Nilsson, O.G. Berg, O. Aspevall, G. Kahlmeter, and D.I. Andersson Biological costs and mechanisms of fosfomycin resistance in Escherichia coli Antimicrob Agents Chemother 47 2003 2850 2858
30. A. Kronenberg, S. Koenig, S. Droz, and K. Mühlemann Active surveillance of antibiotic resistance prevalence in urinary tract and skin infections in the outpatient setting Clin Microbiol Infect 17 2011 1845 1851